- Home
- GRI vs ISPC Comparison
GRI vs ISPC Comparison
Compare GRI & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- ISPC
- Stock Information
- Founded
- GRI 2018
- ISPC 2009
- Country
- GRI United States
- ISPC United States
- Employees
- GRI N/A
- ISPC N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- ISPC Precision Instruments
- Sector
- GRI Health Care
- ISPC Health Care
- Exchange
- GRI Nasdaq
- ISPC Nasdaq
- Market Cap
- GRI 3.2M
- ISPC 3.1M
- IPO Year
- GRI N/A
- ISPC 2021
- Fundamental
- Price
- GRI $1.26
- ISPC $0.94
- Analyst Decision
- GRI Strong Buy
- ISPC
- Analyst Count
- GRI 2
- ISPC 0
- Target Price
- GRI $22.00
- ISPC N/A
- AVG Volume (30 Days)
- GRI 112.3K
- ISPC 51.4K
- Earning Date
- GRI 08-13-2025
- ISPC 08-05-2025
- Dividend Yield
- GRI N/A
- ISPC N/A
- EPS Growth
- GRI N/A
- ISPC N/A
- EPS
- GRI N/A
- ISPC N/A
- Revenue
- GRI N/A
- ISPC $8,058,631.00
- Revenue This Year
- GRI N/A
- ISPC $35.93
- Revenue Next Year
- GRI N/A
- ISPC N/A
- P/E Ratio
- GRI N/A
- ISPC N/A
- Revenue Growth
- GRI N/A
- ISPC N/A
- 52 Week Low
- GRI $1.10
- ISPC $0.86
- 52 Week High
- GRI $43.69
- ISPC $11.80
- Technical
- Relative Strength Index (RSI)
- GRI 40.16
- ISPC 37.62
- Support Level
- GRI $1.28
- ISPC $0.86
- Resistance Level
- GRI $1.45
- ISPC $0.97
- Average True Range (ATR)
- GRI 0.11
- ISPC 0.06
- MACD
- GRI 0.03
- ISPC -0.02
- Stochastic Oscillator
- GRI 29.30
- ISPC 18.79
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.